Credit Suisse First Boston is the lead manager on Royalty Pharma’s pending pharmaceutical patent-backed deal, currently in the marketing stages. This transaction, a follow-up to the Zerit-backed BioPharma Royalty Trust I, is said to be backed by a broader pool of patents. WestLB London agented the first transaction (see ASR 3/24).
Access to a full range of industry content, analysis and expert commentary.
No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.
Have an account? Sign In